Local endovascular delivery, gene therapy, and cell transplantation for peripheral arterial disease.
Advances in catheter technology, gene identification, and cell biology may provide novel treatment options for patients with peripheral arterial disease (PAD) who are not candidates for standard revascularization procedures. Animal studies and recent results in human beings suggest that transfer of growth factors or regulatory genes and transplantation of progenitor cells may provide novel therapy options by inducing therapeutic angiogenesis or by inhibiting restenosis. This review will discuss the development of a variety of catheters for localized endovascular delivery, as well as the various cellular and genetic strategies that exist to restore blood flow to ischemic tissue and to reduce neointimal hyperplasia.
Opie
Shaun R
SR
Department of Cell and Gene Research, Arizona Heart Institute and Foundation, Phoenix, Arizona 85016, USA. SOpie@azheart.com
Dib
Nabil
N
D000818:Animals; D001157:Arterial Occlusive Diseases / Q000628:therapy*; D001161:Arteriosclerosis / Q000628:therapy; D002404:Catheterization; D003097:Collateral Circulation / Q000502:physiology; D003251:Constriction, Pathologic; D005346:Fibroblast Growth Factors / Q000627:therapeutic use; D015316:Genetic Therapy; D006801:Humans; D018919:Neovascularization, Physiologic; D016491:Peripheral Vascular Diseases / Q000628:therapy*; D012008:Recurrence; D033581:Stem Cell Transplantation; D015607:Stents; D014161:Transduction, Genetic; D042461:Vascular Endothelial Growth Factor A / Q000627:therapeutic use
D042461:Vascular Endothelial Growth Factor A; D005346:Fibroblast Growth Factors